RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345

Recent progress on nuclear receptor RORγ modulators

(2016) Patrick Cyr et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Retinoid-related orphan receptor gamma t (RORγt) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742

(2016) Christian Gege   EXPERT OPINION ON THERAPEUTIC PATENTS

RORγ antagonists and inverse agonists: a patent review

(2016) Sarah M. Bronner et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists

(2015) Benjamin P. Fauber et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Retinoid-related orphan receptor γ t modulators: comparison of Glenmark’s me-too patent application (WO2015008234) with the originator application from Merck Sharp and Dohme (WO2012106995)

(2015) Christian Gege   EXPERT OPINION ON THERAPEUTIC PATENTS

CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure

(2015) Zoran Rankovic   JOURNAL OF MEDICINAL CHEMISTRY

ROR nuclear receptors: structures, related diseases and drug discovery

(2014) Yan Zhang et al.   ACTA PHARMACOLOGICA SINICA

Modulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc)

(2014) Benjamin P. Fauber et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis of Enantiomerically Pure 2-Heteroaromatic-Substituted 1,2-Amino Alcohols from Chiral tert-Butanesulfinyl Aldimines

(2014) Yantao Chen et al.   SYNTHESIS-STUTTGART

Human Ether-a-Go-Go-Related Gene Channel Blockers and its Structural Analysis for Drug Design

(2013) N. S. Hari Narayana Moorthy et al.   CURRENT DRUG TARGETS

Targeting Orphan Nuclear Receptors for Treatment of Metabolic Diseases and Autoimmunity

(2012) Thomas P. Burris et al.   CHEMISTRY & BIOLOGY

Targeting IL-17 and TH17 cells in chronic inflammation

(2012) Pierre Miossec et al.   NATURE REVIEWS DRUG DISCOVERY

Follow-on drugs: How far should chemists look?

(2011) Fabrizio Giordanetto et al.   DRUG DISCOVERY TODAY

The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor- /  Inverse Agonist

(2009) N. Kumar et al.   MOLECULAR PHARMACOLOGY